NANOBIOTIX (EPA:NANO)

PRESS RELEASE

published on 03/27/2025 at 21:15, 10 months 2 days ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Nanobiotix announces first data from the completed dose escalation part of a Phase 1 study evaluating NBTXR3 (JNJ-1900) as a 2L+ therapy for patients with locally advanced NSCLC. The study shows favorable safety and injection feasibility, with promising survival data

NSCLC NANOBIOTIX NBTXR3 Phase 1 Study Dose Escalation
BRIEF

published on 03/20/2025 at 21:20, 10 months 9 days ago

Nanobiotix Unveils Phase 1 Results at European Lung Cancer Congress

Biotechnology NANOBIOTIX Lung Cancer Phase 1 JNJ-1900
PRESS RELEASE

published on 03/20/2025 at 21:15, 10 months 9 days ago

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Nanobiotix announces presentation of data from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference. Studies highlight safety, efficacy, and collaboration strategies

Collaboration NANOBIOTIX Lung Cancer JNJ-1900 Phase 1 Studies
BRIEF

published on 03/17/2025 at 21:20, 10 months 12 days ago

NANOBIOTIX Extends its Financial Horizon until mid-2026

License Agreement NANOBIOTIX NBTXR3 Financial Visibility Janssen
PRESS RELEASE

published on 03/17/2025 at 21:15, 10 months 12 days ago

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
Nanobiotix strengthens financial position by amending global licensing agreement for JNJ-1900 (NBTXR3), extending cash visibility to mid-2026. Details of the amendment and future potential milestone payments outlined

Financial Position Milestone Payments NANOBIOTIX JNJ-1900 Global Licensing Agreement
BRIEF

published on 03/13/2025 at 22:20, 10 months 16 days ago

Nanobiotix Reports Voting Rights and Share Capital Details

Euronext Paris Voting Rights Financial Transparency NANOBIOTIX Shares Outstanding
PRESS RELEASE

published on 03/13/2025 at 22:15, 10 months 16 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix reports voting rights and shares capital. Detailed breakdown of outstanding shares and voting rights presented. Company overview and contact information included

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF

published on 02/12/2025 at 22:20, 11 months 17 days ago

Nanobiotix: Details on Voting Rights and Shares in January 2025

Euronext Paris Voting Rights Actions Nasdaq NANOBIOTIX
PRESS RELEASE

published on 02/12/2025 at 22:15, 11 months 17 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix announces voting rights and shares capital details. Company listed on Euronext Paris and Nasdaq. Focus on disruptive therapeutic approaches

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF

published on 12/17/2024 at 22:20, 1 year 1 month ago

NANOBIOTIX Prepares its Revolutionary Virtual Event

Cancer NANOBIOTIX Curadigm Nanotherapeutic Technology Intravenous Medications

Published on 01/30/2026 at 14:00, 5 hours 20 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 10 hours 45 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 11 hours 20 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 17 hours 5 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 19 hours 20 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 18:31, 48 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/30/2026 at 18:30, 49 minutes ago

HOL-Holdings in Company
Published on 01/30/2026 at 18:23, 56 minutes ago

TVR-Total Voting Rights
Published on 01/30/2026 at 18:17, 1 hour 2 minutes ago

POS-Transaction in Own Shares
Published on 01/30/2026 at 18:17, 1 hour 2 minutes ago

Holding(s) in Company

View all EQS

Published on 01/30/2026 at 17:45, 1 hour 35 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 11 hours 20 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 1 hour ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 1 hour ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 1 hour ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News